RT @BreastTexas: Neoadjuvant chemo provides so many benefits for the appropriate #breastcancer pt, here’s more! #bcsm #bccww #chemo #@HemOn…@HemOn…?src=hashtag_click">#@HemOn…>
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT @NicoleKuderer: While this may not yet be the definitive Validation of Residual Cancer Burden (RCB) as Prognostic Factor for #brcm, RCB…
RT @NicoleKuderer: While this may not yet be the definitive Validation of Residual Cancer Burden (RCB) as Prognostic Factor for #brcm, RCB…
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT @NicoleKuderer: While this may not yet be the definitive Validation of Residual Cancer Burden (RCB) as Prognostic Factor for #brcm, RCB…
RT @NicoleKuderer: While this may not yet be the definitive Validation of Residual Cancer Burden (RCB) as Prognostic Factor for #brcm, RCB…
While this may not yet be the definitive Validation of Residual Cancer Burden (RCB) as Prognostic Factor for #brcm, RCB tells us that many non-pCR pts are also cured. https://t.co/eGogs1Cr9z
RT @BreastTexas: Neoadjuvant chemo provides so many benefits for the appropriate #breastcancer pt, here’s more! #bcsm #bccww #chemo #@HemOn…@HemOn…?src=hashtag_click">#@HemOn…>
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT @annepeledmd: Yet one more good reason to consider neoadjuvant chemotherapy - ability to use residual tumor burden to 1) provide prognos…
RT @annepeledmd: Yet one more good reason to consider neoadjuvant chemotherapy - ability to use residual tumor burden to 1) provide prognos…
RT @annepeledmd: Yet one more good reason to consider neoadjuvant chemotherapy - ability to use residual tumor burden to 1) provide prognos…
RT @annepeledmd: Yet one more good reason to consider neoadjuvant chemotherapy - ability to use residual tumor burden to 1) provide prognos…
RT @BreastTexas: Neoadjuvant chemo provides so many benefits for the appropriate #breastcancer pt, here’s more! #bcsm #bccww #chemo #@HemOn…@HemOn…?src=hashtag_click">#@HemOn…>
RT @RICKLIN4TH: Residual disease after treatment leads to a poorer prognosis.This identifies a group of patients needing further adjuvant t…
Neoadjuvant chemo provides so many benefits for the appropriate #breastcancer pt, here’s more! #bcsm #bccww #chemo #@HemOncWomenDocs@HemOncWomenDocs?src=hashtag_click">#@HemOncWomenDocs>
RT @RICKLIN4TH: Residual disease after treatment leads to a poorer prognosis.This identifies a group of patients needing further adjuvant t…
RT @ChocolatiereP: Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy https://t…
Residual disease after treatment leads to a poorer prognosis.This identifies a group of patients needing further adjuvant therapies rather than watch and wait follow up.
RT @annepeledmd: Yet one more good reason to consider neoadjuvant chemotherapy - ability to use residual tumor burden to 1) provide prognos…
RT @annepeledmd: Yet one more good reason to consider neoadjuvant chemotherapy - ability to use residual tumor burden to 1) provide prognos…
Yet one more good reason to consider neoadjuvant chemotherapy - ability to use residual tumor burden to 1) provide prognostic info to patients and 2) guide potential additional therapy to reduce recurrence risk #bcsm
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
RT SocSurgOnc RT AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTherapy. https://t.co/aTrpQHAD8h McMastersKelly SocSurgOnc https://t.co/oSfdLh3Fd7
RT @AnnSurgOncol: DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTh…
DECEMBER ISSUE: Validation of Residual Cancer Burden as Prognostic Factor for #BreastCancer Patients After #NeoadjuvantTherapy. https://t.co/SMZTRpd7O7 @McMastersKelly @SocSurgOnc https://t.co/VItCzWs4Ub